De volgende waarschuwingen zijn opgetreden: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warning [2] Undefined array key "lockoutexpiry" - Line: 94 - File: global.php PHP 8.0.30 (Linux)
|
Cancer Biomarkers Market share will expand till 2030 - Afdrukversie +- Forum Technology Interest Group Erpe-Mere (http://www.on4lar.be/forum) +-- Forum: Onze club (http://www.on4lar.be/forum/forumdisplay.php?fid=1) +--- Forum: Het forum (http://www.on4lar.be/forum/forumdisplay.php?fid=2) +--- Discussie: Cancer Biomarkers Market share will expand till 2030 (/showthread.php?tid=784) |
Cancer Biomarkers Market share will expand till 2030 - Stella01 - 07-28-2021 Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2021–2030.” The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes: · A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies. · An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+). · An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups). · Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio). · A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs. · A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs. · A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years. · A discussion on various steps involved in development operations of companion diagnostics · A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Request for Customization: https://www.rootsanalysis.com/reports/253/request-customization.html Type of test · Laboratory Developed Tests (LDTs) · Companion Diagnostic Tests (CDx) Type of disease indication · Breast cancer · Blood cancer · Colon / Colorectal cancer · Lung Cancer · Melanoma · Prostate Cancer Type of cancer biomarker · TMB · MSI / MMR · TILs Type of analytical technique · Next Generation Sequencing (NGS) · Polymerase Chain Reaction (PCR) · Immunohistochemistry (IHC) · Others Key geographical regions · North America · Europe · Japan · China · Australia Key companies covered in the report · Foundation Medicine · NeoGenomics Laboratories · Novogene · Q2 Solutions · Personal Genome Diagnostics · Dr Lal Path Labs · Shenzhen Yuce Biotechnology Inquiry before Purchasing: https://www.rootsanalysis.com/reports/253/request-sample.html Please Visit Our Upcoming Reports
|